Of the 1,000-2,600 people who get meningococcal disease each year, one-third are teens and young adults. Ten percent to 15% of those who get sick with the disease will die, even with antibiotic treatment. As many as 20% will have permanent side effects, such as hearing loss or brain damage.
The immunization can help prevent this serious disease.
In the U.S., three meningococcal vaccines
- Meningococcal polysaccharide vaccine (MPSV4), sold as Menomune
- Meningococcal conjugate vaccine (MCV4), sold as Menactra, MenHibrix, and Menveo.
- Serogroup B meningococcal vaccine, sold as Trumenba and Bexsero.
The CDC recommends a meningococcal vaccine for:
- All children ages 11-18 or certain younger high-risk children
- Anyone who has been exposed to meningitis during an outbreak
- Anyone traveling to or living where meningitis is common, such as in sub-Saharan Africa
- Military recruits
- People with certain immune system disorders or a damaged or missing spleen
Your preteen or teen shouldn't
get the meningococcal vaccine if he or she:
- Has ever had Guillain-Barre syndrome
- Is moderately or severely ill (reschedule when you are well)
- Has had a severe, life-threatening allergic reaction to a meningococcal vaccine before or to any vaccine component
Keyword: bacterial meningitis vaccination; bacterial meningitis vaccinations; bacterial meningitis vaccine